Altria Group stock gains as FDA lawsuit hits

Published on 09/02/2026 at 21:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Altria Group stock gains as the company sues the FDA over tobacco product reviews. The latest quarter brought USD 5.36 billion in revenue, EPS of USD 1.48, and 2026 guidance of USD 5.61 to USD 5.72.

Isometrische Illustration: Tabak-Lieferkette – Farm, Fabrik und Lager — Altria Group Inc. US02209S1033 – Isometrische 3D-Grafik der Tabak-Lieferkette von Anbau über Verarbeitung bis Handel, Illustration mit AI erstellt.

Altria Group Inc. stock (ISIN US02209S1033) trades around USD 69.63 after a 1.7 percent move, while market capitalization stood at USD 116.26 billion and the 52-week range stretched from USD 54.70 to USD 77.05 as of September 2, 2026. Reuters reported on September 2, 2026, that the company sued the U.S. Food and Drug Administration over the tobacco product review process.

FDA case gives the stock a fresh peg

According to the Reuters report, Altria says the review process has slowed approval decisions for tobacco products. That legal step gives the stock a concrete catalyst on September 2, 2026, and it arrives while the shares sit near the upper half of the 52-week band.

MarketBeat said on September 1, 2026, that Altria shares rose 1.7 percent to USD 69.63, with 9.82 million shares changing hands and a consensus target price of USD 70.11. The same report also noted a quarterly dividend increase from USD 1.06 to USD 1.11 per share, lifting the annualized payout to USD 4.44.

Revenue and EPS stay central

For the quarter ended July 30, 2026, Altria reported USD 5.36 billion in revenue and EPS of USD 1.48, while Wall Street expected USD 1.50. Revenue rose 1.2 percent from the prior-year quarter, and the company set FY 2026 adjusted EPS guidance at USD 5.61 to USD 5.72.

That combination matters because the stock is trading at about 14.69 times earnings, so the market is balancing a stable cash return profile against only modest profit growth. MarketBeat also cited a net margin of 33.99 percent, which shows how much of the top line still turns into earnings even after the earnings miss.

Dividend still drives attention

Altria's quarterly dividend of USD 1.11 per share supports an annualized payout of USD 4.44, and the yield cited in the same MarketBeat report was 6.4 percent. The payout ratio was 89.45 percent, so the dividend remains a central part of the equity story.

For investors, the key number is not only the yield but also the spread between USD 5.61 and USD 5.72 in 2026 guidance and the latest quarterly EPS of USD 1.48. That gap shows why every update to the operating outlook still moves the stock.

Marlboro stays the core

Philip Morris USA remains the main cigarette business inside Altria Group Inc., which still relies on U.S. tobacco demand and pricing power. The July 30, 2026 quarter showed that the core franchise can still deliver USD 5.36 billion in revenue even as EPS came in below consensus.

USD 69.63 level

Altria Group stock ended the latest cited session at USD 69.63, with a market value of USD 116.26 billion and a 52-week range from USD 54.70 to USD 77.05 as of September 2, 2026. That leaves the shares close to the middle of the yearly band rather than at an extreme.